Skip to main content

Table 2 Selected parameters for estimating cost-effectiveness of HPV vaccination using the PRIME model

From: Cervical cancer treatment costs and cost-effectiveness analysis of human papillomavirus vaccination in Vietnam: a PRIME modeling study

No

Parameter

Average value/value

Range

Source

1

Vaccine delivery cost per FIG

$ 10.4

$ 9.5-$ 11.3

Costing study

2

Cancer treatment cost

  

Costing study

 

Scenario 5 (IA1 - IIB proximal treated by Radical hysterectomy)

$ 368.3

N/A

 
 

Scenario 6 (IA1 - IIB proximal treated by Radical hysterectomy + Chemoradiation)

$ 8700.1

N/A

 
 

Scenario 7 (IA1 - IIB proximal treated by Radical hysterectomy + Radio therapy (Intr))

$ 2209.6

N/A

 
 

Scenario 8 (IA1 - IIB proximal treated by Radical hysterectomy + Radio-therapy (External beam))

$ 1449.9

N/A

 
 

Scenario 9 (IIB distant – IVB treated by Chemoradiation)

$ 11448.1

N/A

 
 

Scenario 10 (IIB distant – IVB treated by Radio therapy (Intra + External))

$ 5166.52

N/A

 
 

Scenario 11 (average cost of all scenarios)

$ 4,890.44

N/A

 

3

DALYs lost per non-fatal cancer episode

0.7

 

Literature review

4

DALYs lost per fatal cancer episode (excluding life years lost)

0.8

 

Literature review

5

Epidemiological data

  

Literature review

 

Cervical cancer incidence in 2012

6.1 per 100000

 

GLOBOCAN 2012

20.5 per 100000

26.7 per 100000

31.3 per 100000

32.1 per 100000

26.2 per 100000

20.5 per 100000

13 per 100000

 

Cervical cancer mortality in 2012

1.1 per 100000

 

GLOBOCAN 2012

6.5 per 100000

15.1 per 100000

18.8 per 100000

21.3 per 100000

21.8 per 100000

20 per 100000

16.1 per 100000

5.3 per 100000

 

All-cause mortality in 2012

100 - 52 800 per 100 000 (depending on age)

 

National statistics